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ABSTRACT
Objective To explore the interaction effects between
cardiac interatrial right-to-left shunt (RLS) and
proatherosclerotic factors on the risk of brain ischaemia.
Design Multicentre Italian caseecontrol study.
Setting University hospitals.
Participants 588 patients with cryptogenic stroke (CS)
aged #45 years and 585 control subjects consecutively
enrolled as part of the Italian Project on Stroke in Young
Adults.
Methods Interaction effects between RLS and an
individual proatherosclerotic score computed from the
number of conventional vascular risk factors for the risk
of CS were investigated. Data were examined by logistic
regression models and expressed as interaction OR or
interaction risk difference (RD).
Results CS risk increased with increasing number of
proatherosclerotic factors in subjects without RLS (OR
2.73; 95% CI 1.98 to 3.76; RD +0.246; 95% CI +0.17 to
+0.32; for subjects with one or more factors), but was
higher in subjects with RLS and no additional
proatherosclerotic factors (OR 5.14; 95% CI 3.49 to 7.58;
RD +0.388; 95% CI +0.31 to +0.47) compared with
subjects without RLS and no risk factors. Negative
interaction and antagonistic effects between RLS and
proatherosclerotic factors were observed (interaction OR
0.52; 95% CI 0.31 to 0.91; interaction RD 0.17; 95% CI
0.29 to 0.05).
Conclusions The influence of RLS on the risk of CS
decreases with increasing number of atherosclerotic
factors, and is highest when such factors are absent.
Individual proatherosclerotic profiles may help to identify
patients with CS whose patent foramen ovale is probably
pathogenic.
INTRODUCTION
The role of patent foramen ovale (PFO) as a risk
factor for stroke is controversial. Although the
numerous caseecontrol studies conducted thus far
have demonstrated an increased prevalence of this
cardiac abnormality and interatrial right-to-left
shunt (RLS) in patients with cryptogenic stroke
(CS) compared with patients with stroke of known
cause,1 two population-based prospective studies
did not conﬁrm these ﬁndings,2 3 questioning the
concept of increased stroke risk from this anatom-
ical variant. Apart from the obvious differences in
the design of the studies, one likely reason for these
inconsistencies is the substantial heterogeneity of
patients with RLS and otherwise unexplained
stroke, as a consequence of the inﬂuence that
additional cofactors might have on this relation.
Actually, numerous factors can potentially affect
the degree of association and thus the likelihood
that a PFO in the setting of CS is an incidental
ﬁnding, leading us to assume that only speciﬁc
subgroups of PFO carriers are exposed to a relevant
stroke risk. Identifying patients whose stroke is
probably attributable to PFO may be useful in risk-
predictive modelling aimed at reducing treatment
effect heterogeneity and, on an individual level, in
selecting the most appropriate option for secondary
prevention.4 In this regard, sparse reports have
suggested, although not always in a consistent
direction, that RLS is associated with CS when
patients are younger and have a lower prevalence of
conventional atherosclerotic risk factors.5e10
However, since none of these analyses have
included a control group composed of stroke-free
subjects whose PFO status had been determined,
any estimation about how the risk of stroke in PFO
carriers may vary depending on the presence or
absence and burden of such cofactors is precluded.
The purpose of the present study is to provide
such an estimation based on a caseecontrol anal-
ysis including a large, homogeneous and well-
characterised patient population from the Italian
Project on Stroke in Young Adults (IPSYS). In
particular, we sought to explore any interaction
effect between RLS and atherosclerotic cofactors on
CS risk.
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SUBJECTS AND METHODS
The study was approved by the local ethics committee.
Informed consent was provided by all study participants.
Study group
Cases
Stroke patients were recruited in the setting of the IPSYS. IPSYS
is a countrywide network of neurological centres with special
interest in cerebral ischaemia at a young age across Italy (see
online appendix), aimed at recruiting patients with ﬁrst-ever
acute ischaemic stroke, who fulﬁl the criteria age 18e45 years
and CT- or MRI-proven cerebral infarction, in the setting of
a hospital-based, multicentre, observational study.11 Centres are
included in the network provided that the recruitment process
of stroke cases takes place prospectively. Stroke was deﬁned as
a sudden loss of global or focal cerebral function that persisted
for >24 h with a probable vascular cause. Ischaemic strokes due
to sinus venous thrombosis, vasospasm after subarachnoid
haemorrhage or cardiac surgery, or occurring as an immediate
consequence of trauma, and iatrogenic strokes were excluded.
For the purpose of the present analysis, we screened datasets
from patients included between January 2000 and July 2009.
Clinical and laboratory investigations
All patients underwent an extensive aetiological workup aimed
at determining the most likely mechanism of stroke in each case;
it included complete blood cell count, biochemical proﬁle,
urinalysis, 12-lead ECG, chest roentgenography, Doppler ultra-
sonography with frequency spectral analysis and B-mode echo-
tomography of the cervical arteries, transcranial Doppler
ultrasonography, and CTand/or MR angiography to investigate
extracranial and intracranial vessels. The performance of speci-
alised coagulation testing (including prothrombin and activated
partial thromboplastin times, antibodies to phospholipid,
ﬁbrinogen, protein C, protein S, activated protein C resistance,
antithrombin III, genotyping to detect factor V Leiden and the
G20210A mutation in the prothrombin gene) was left to the
discretion of the investigator in charge of the patient. Trans-
thoracic and/or transoesophageal echocardiography was
performed to rule out cardiac sources of emboli. In particular,
interatrial RLS was assessed in all patients by transoesophageal
echocardiography with a contrast study and Valsalva manoeuvre
(c-TEE) and/or transcranial Doppler sonography with intrave-
nous injection of agitated saline (c-TCD). An RLS was consid-
ered present if any microbubble was seen in the left atrium
within three cardiac cycles from maximum right atrial opaciﬁ-
cation on echocardiography.12 c-TCD was performed according
to the Venice Consensus Conference.13 Brieﬂy, it consists of the
injection of 9 ml saline solution and 1 ml air mixed with a three-
way stopcock by exchange of saline/air mixture between the
syringes and injected as a bolus as a contrast-enhancing agent
into the right cubital vein 5 s before the start of a 10 s Valsalva
manoeuvre, while recording the ﬂow velocity of the middle
cerebral artery, insonated through the temporal window on the
right side at a depth of 50e60 mm, with a handheld probe. The
appearance of transient spikes on the velocity spectral curve is
considered positive for interatrial RLS. The method has an
overall diagnostic accuracy comparable to that of c-TEE.14
Patients were categorised according to an aetiological classiﬁca-
tion based on the Trial of Org 10172 in Acute Stroke Treatment
criteria, accommodated and validated for stroke in the young.15
Deﬁnite causes of stroke included the following aetiological
categories: (1) atherosclerotic vasculopathy, (2) non-atheroscle-
rotic vasculopathy, (3) small-vessel disease, (4) probable cardi-
oembolism, (5) haematological cause (coagulopathies), and (5)
migrainous stroke. CS was deﬁned as cerebral infarcts that did
not meet the criteria for one of the categories mentioned above
and fulﬁlled the diagnostic criteria for the categories (1) cardiac/
transcardiac embolism with RLS only, (2) use of oral contra-
ceptive or exogenous oestrogen and (3) indeterminate.15
Risk factor definition
The following risk factors for premature cerebral ischaemia were
retained: hypertension, diabetes mellitus, cigarette smoking and
hypercholesterolaemia. These variables were deﬁned and dicho-
tomised as follows: hypertension (systolic blood pressure
$140 mm Hg and diastolic blood pressure $90 mm Hg in two
separate measurements after the acute phase or use of antihy-
pertensive drugs before recruitment), diabetes mellitus (history
of diabetes, use of hypoglycaemic agent or insulin, or fasting
glucose $126 mg/dl), current smoking (including former
smokers who had quit smoking for 6 months before the index
event) and hypercholesterolaemia (serum cholesterol levels
$220 mg/dl or use of cholesterol-lowering drugs).
Control subjects
Staff members of participating hospitals, with no known history
of vascular disease, aged #45 years, and from the same ethnic
background as the cases were invited to participate in the study
as controls. Demographic variables, vascular risk factors, and the
presence of RLS on c-TCD were assessed in all these subjects
according to the diagnostic criteria applied to the cases.11
Statistical analysis
On the basis of the number of the above mentioned cardiovas-
cular risk factors, we computed an individual proatherosclerotic
score (PS, from 0 to 4) and deﬁned a binary variable (0 vs 1 or
more). Descriptive differences among study groups were exam-
ined with the c2 test, and by analysis of variance F test, when
appropriate. Logistic regression models were planned to examine
the conditional (‘pure’) effects and any interaction (multiplica-
tive or additive) effect of RLS and PS on the disease outcome,
adjusted for age and gender. The interaction effect deﬁnes the
situation where the effect of RLS on CS is different across strata
of PS, or, vice versa, the effect of PS on CS is different across
congenital anomaly groups. Multiplicative interaction occurs
when the combined effect is larger (positive interaction) or
smaller (negative interaction) than the product of the pure
Table 1 Demographic characteristics of patients with cryptogenic
stroke and control subjects
Characteristic
Cryptogenic stroke
(n[588)
Control Subject
(n[585) p Value
Age (years), mean 6 SD 35.367.5 34.068.0 0.003
Sex, women 302 (51.4) 310 (53.0) 0.576
Hypertension 110 (18.7) 27 (4.6) <0.001
Diabetes mellitus 16 (2.7) 14 (2.4) 0.722
Current smokers 216 (36.7) 152 (26.0) <0.001
Hypercholesterolaemia 141 (24.1) 68 (11.6) <0.001
Proatherosclerotic score <0.001
0 242 (41.3) 361 (61.7)
1 235 (40.1) 190 (32.5)
2 82 (14.0) 31 (5.3)
3 25 (4.3) 3 (0.5)
4 2 (0.3) 0 (0.0)
Right-to-left shunt 279 (47.5) 119 (20.3) <0.001
Values are number (%) unless otherwise stated.
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individual effects. Additive interaction occurs when the
combined effect is larger (synergism) or smaller (antagonism)
than the sum of the pure individual effects. The degree of
interaction as a departure from multiplicative or additive scales,
measured by the interaction OR or interaction risk difference
(RD) indices, was derived using the logistic regression formulae
in two steps. First, ORs were given as exponentials of logistic
regression parameters16; second, RDs were derived as a simple
function of the ORs considering the maximum Manski bounds
for the RDs in classical caseecontrol studies.17
Results are given within RLS 3 PS strata. Robust (sandwich)
95% CIs were computed, and p<0.05 on a two-sided test was
considered signiﬁcant. Statistical analyses were performed with
SPSS (V.16), and Mplus (V.6.1) packages.
RESULTS
This study targeted 588 patients with CS among the 1017
enrolled in the IPSYS registry (57.8%) and 585 control subjects.
The causes of stroke in the remaining 429 patients were
distributed as follows: large-vessel atherosclerosis and small-
vessel disease in 112 (11.0%) and 55 (5.4%) cases, respectively,
non-atherosclerotic vasculopathy in 179 (17.6%) cases, probable
cardiac embolism in 22 (2.1%) cases, and other aetiologies in the
remaining 61 (5.9%) cases. Demographic characteristics and
distribution of risk factors in patients with CS and control
subjects are summarised in table 1. Patients with CS more often
had hypertension and hypercholesterolaemia, were more often
smokers, and, overall, were more likely to have an unfavourable
vascular risk proﬁle than control subjects. RLS was more
common in the group of patients (n¼279; 47.5%) than in the
group of control subjects (n¼119; 20.3%).
As summarised in table 2, the ‘pure’ risk of CS increased with
increasing number of proatherosclerotic risk factors in subjects
without RLS (OR 2.73; 95% CI 1.98 to 3.76; RD +0.246; 95% CI
+0.17 to +0.32; for subjects with one or more factor), but was
higher in subjects with RLS and no additional proatherosclerotic
factors (PS 0; OR 5.14; 95% CI 3.49 to 7.58; RD +0.388; 95% CI
+0.31 to +0.47) when compared with subjects without RLS and
without risk factors. A signiﬁcant negative interaction and an
antagonistic effect between RLS and proatherosclerotic factors
were observed. The increase in CS risk with increasing number
of proatherosclerotic factors was smaller in subjects with RLS
than in subjects without RLS (interaction OR 0.526; 95% CI
0.31 to 0.91; interaction RD 0.172; 95% CI 0.29 to 0.05;
ﬁgure 1). In other words, the inﬂuence of RLS on the risk of CS
was higher when atherosclerotic factors were absent (PS, 0) and
reduced (if anything) with an increasing number of these factors
(PS $1).
DISCUSSION
Despite recent progress in elucidation of the mechanisms linking
RLS and ischaemic stroke, identiﬁcation of patients whose
interatrial abnormality is likely to play a pathogenic role is still
a matter of debate. It is estimated that at least one-third of RLSs
discovered in patients with CS are incidental ﬁndings and are
unrelated to stroke.18 The prevailing idea is that stroke patients
who carry an RLS should be subgrouped on the basis of the
individual likelihood that the index event is attributable to this
anatomical variant and that the presence/absence of coexistent
factors thought to modulate the risk of disease may be used to
make such an estimation.4 18 The results of our study provide
evidence that the associated proatherosclerotic conditions is one
of these factors, the risk of paradoxical embolisation being
increased in subjects with a lower prevalence of conventional
stroke risk factors and even higher when they are absent. The
increasing burden of these factors had a smaller effect on the risk
of CS in patients with RLS than in patients with no evidence of
interatrial abnormality. These ﬁndings support the notion that
different pathogenic mechanisms are operating in the occurrence
of cerebral ischaemia in young adults with RLS and that not all
Table 2 Right-to-left shunt and proatherosclerotic score interaction effect on the risk of cryptogenic
stroke
Right-to-left
shunt Proatherosclerotic score Cases* Controls OR (95% CI) RD (95% CI)y
Absent 0 114 (19.8) 303 (51.8) 1 0
1 or more 181 (31.5) 163 (27.9) 2.73 (1.98 to 3.76) +0.246 (+0.17 to +0.32)
Present 0 125 (21.8) 62 (10.6) 5.14 (3.49 to 7.58) +0.388 (+0.31 to +0.47)
1 or more 154 (26.9) 57 (9.7) 7.38 (4.97 to 11.0) +0.462 (+0.38 to +0.54)
Values for cases and controls are number (%).
*14 cases had missing values.
yRDs were computed using the maximum value of Manski bounds on the risk difference in caseecontrol studies.17
Interaction OR (95% CI) ¼7.38/(2.7335.14)¼0.526 (0.31 to 0.91).
Interaction risk difference (95% CI) ¼0.46(0.24+0.38) ¼0.17 (0.29 to 0.05).
RD, risk difference.
Figure 1 Trajectory of cryptogenic
stroke risk presented as risk difference
(A) and OR (B) according to right-to-left
shunt (RLS) status and
proatherosclerotic score.
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the detected RLSs have a pathophysiological relationship to the
index stroke. The practical implication of these ﬁndings is
noteworthy. Stratifying patients with RLS and otherwise CS
into subgroups of higher and lower RLS-attributable risk based
on individual proatherosclerotic proﬁles is a simple and effective
way to help reduce patient heterogeneity, allowing more accu-
rate selection of those with probable paradoxical embolism for
future therapeutic trials and leading to more targeted treatment
approaches.18 Our study adds to the accumulating evidence of
a lower prevalence of conventional stroke risk factors among CS
patients with PFO than among those without PFO,5e10
although the different setting and design of the previous studies
and the lack of a group of control subjects make their results not
entirely comparable to ours. Also, besides the obvious implica-
tion in the process of PFO-carrier stratiﬁcation, these ﬁndings
indirectly reinforce the notion that cardiac RLS probably has
a role in the occurrence of brain ischaemia.
STRENGTHS AND LIMITATIONS OF THE STUDY
The study was based on a large and representative cohort with
a narrow age range, comprehensive data on conventional risk
factors for cerebral ischaemic disease, accurate assessment of
RLS, reliable ascertainment of stroke aetiology, and the use of
a group of stroke-free control subjects whose RLS status was
systematically determined. Another strength of our study was
the use of a logistic modelling approach to estimate both
multiplicative and additive interaction effects, instead of the
simple regression methods that are typically used in PFO-stroke
epidemiological studies and are often inadequate for estimating
causal effects when the causal structures of interest are complex.
This enabled us to look in detail at interactions, allowing
a detailed comparison of risk factor proﬁles between PFO carriers
who had a stroke and those who did not, and adds to the
generalisability of our results.
Several considerations and limitations may affect the inter-
pretation of our ﬁndings. The c-TCD technique prevents the
assessment of atrial septal aneurysmdbulging of the interatrial
wall sometimes associated with RLSdwhich has been thought
to increase the risk of brain embolism. Nor could we estimate
the inﬂuence that RLS diameterda marker that may allow
identiﬁcation of patients at high risk of cerebral ischaemiadmay
have on the results. This limits interpretation of the data on the
strength of the relation between RLS and proatherosclerotic
factors on CS occurrence. Also, since the group of controls was
recruited among hospital employees, we cannot theoretically
rule out the possibility of biased caseecontrol matching, as
a consequence of the presumed healthier lifestyle of these
subjects. However, since the prevalence of risk factors, as well as
of RLS, in our subgroup of controls is similar to that found in
other groups of healthy individuals from the same geographical
area,19 20 we believe such a potential bias did not play a part in
our analysis. Finally, because of the young age of our cohort,
generalising these ﬁndings to other age groups in which cardiac
RLS is thought to be pathogenic21 should be performed with
caution.
CONCLUSION
In conclusion, the results of our analysis provide evidence of
a signiﬁcant difference in atherosclerotic risk factor proﬁle
according to the presence of interatrial RLS in patients with CS
and a differential inﬂuence of such a cardiac abnormality on the
risk of CS according to the number of these factors. Although
a causal relationship between RLS and CS remains difﬁcult to
ascertain at an individual level, these ﬁndings may be useful
for the identiﬁcation of patients whose RLS is likely to be
pathogenic.
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